Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With Ivacaftor

25 Nov 2014

Abstract excerpt

BACKGROUND: Ivacaftor improves outcomes in cystic fibrosis (CF) patients with the G551D mutation; however, effects on respiratory microbiology are largely unknown. This study examines changes in CF respiratory pathogens with ivacaftor and correlates them with baseline characteristics and clinical response. METHODS: The G551D Observational Study enrolled a longitudinal observational cohort of US patients with CF...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacterial biofilms and quorum sensing
Share to Cystic Fibrosis Research Advances
Share to Pediatric health and respiratory diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25425629
DOI: 10.1093/cid/ciu944

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pseudomonas aeruginosa in Cystic Fibrosis Patients With G551D-CFTR Treated With IvacaftorPMID 25425629Read ↗

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.Semantic proximity Read ↗

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.Semantic proximity Read ↗

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.Semantic proximity Read ↗

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.Semantic proximity Read ↗

Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation.Semantic proximity Read ↗

Impact of CFTR Modulation on Pseudomonas aeruginosa Infection in People With Cystic Fibrosis.Semantic proximity Read ↗

Impact of elexacaftor/tezacaftor/ivacaftor on bacterial cultures from people with cystic fibrosis.Semantic proximity Read ↗

Individual and Group Response of Treatment with Ivacaftor on Airway and Gut Microbiota in People with CF and a S1251N MutationSemantic proximity Read ↗

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease.Semantic proximity Read ↗

Antibiotic exposure and interpersonal variance mask the effect of ivacaftor on respiratory microbiota composition.Semantic proximity Read ↗

Combining Ivacaftor and Intensive Antibiotics Achieves Limited Clearance of Cystic Fibrosis Infections.Semantic proximity Read ↗

Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.